FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103187519> ?p ?o ?g. }

• W2103187519 endingPage "201" @default.
• W2103187519 startingPage "1197" @default.
• W2103187519 abstract "Evidence from several in vitro systems indicates that cellular responses to DNA topoisomerase II-reactive compounds (i.e., the epipodophyllotoxins and intercalating agents) may be affected by the relative rate of proliferation. Using a human head and neck squamous carcinoma cell line 183A, we have investigated the effect of beta-all-trans-retinoic acid (RA), a substance with known antiproliferative effects, on the DNA cleavage and cytotoxic activities of etoposide and 4'-(acridinylamino)methanesulfon-m-anisidide which interact with topoisomerase II. The effect of RA treatment on the activity of X-radiation and bleomycin, both of which produce free radical mediated effects, was also examined. RA treatment (10 to 20 microM for 72 h) does not significantly influence DNA cleavage induced by X-radiation or bleomycin but decreases DNA cleavage and cytotoxicity mediated by etoposide and 4'-(acridinylamino)methanesulfon-m-anisidide. Further, this effect can be demonstrated at a dose of RA that is minimally growth inhibitory. The inhibitory effect of RA appears to be localized to the nucleus given that similar effects on drug-mediated DNA cleavage can be demonstrated in nuclei isolated from RA-treated cells. However, both drug-stimulated DNA cleavage activity and topoisomerase II catalytic activity are approximately equal in crude nuclear extracts of untreated and RA-treated cells. These data suggest that the resistance to topoisomerase II-reactive drugs induced by RA treatment of 183A cells is not mediated through a direct effect on the enzyme, but, instead, is related to other changes in the nuclear milieu occurring in the initial stages of quiescence such as altered chromatin conformation." @default.
• W2103187519 created "2016-06-24" @default.
• W2103187519 creator A5021085695 @default.
• W2103187519 creator A5045196434 @default.
• W2103187519 creator A5045423620 @default.
• W2103187519 creator A5046742460 @default.
• W2103187519 creator A5054422500 @default.
• W2103187519 creator A5073466449 @default.
• W2103187519 creator A5085188591 @default.
• W2103187519 date "1989-03-01" @default.
• W2103187519 modified "2023-09-26" @default.
• W2103187519 title "Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line." @default.
• W2103187519 cites W177757039 @default.
• W2103187519 cites W1854896859 @default.
• W2103187519 cites W1973057627 @default.
• W2103187519 cites W1979094638 @default.
• W2103187519 cites W1987933754 @default.
• W2103187519 cites W1988613599 @default.
• W2103187519 cites W1992048345 @default.
• W2103187519 cites W2010331255 @default.
• W2103187519 cites W2020120224 @default.
• W2103187519 cites W2021795997 @default.
• W2103187519 cites W2026321751 @default.
• W2103187519 cites W2035179392 @default.
• W2103187519 cites W2046668610 @default.
• W2103187519 cites W2049791242 @default.
• W2103187519 cites W2053211776 @default.
• W2103187519 cites W2056168855 @default.
• W2103187519 cites W2060699167 @default.
• W2103187519 cites W2067141850 @default.
• W2103187519 cites W2080010039 @default.
• W2103187519 cites W2085729093 @default.
• W2103187519 cites W2119687650 @default.
• W2103187519 cites W2128075765 @default.
• W2103187519 cites W2128635872 @default.
• W2103187519 cites W2339318589 @default.
• W2103187519 cites W416019322 @default.
• W2103187519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2537145" @default.
• W2103187519 hasPublicationYear "1989" @default.
• W2103187519 type Work @default.
• W2103187519 sameAs 2103187519 @default.
• W2103187519 citedByCount "2" @default.
• W2103187519 crossrefType "journal-article" @default.
• W2103187519 hasAuthorship W2103187519A5021085695 @default.
• W2103187519 hasAuthorship W2103187519A5045196434 @default.
• W2103187519 hasAuthorship W2103187519A5045423620 @default.
• W2103187519 hasAuthorship W2103187519A5046742460 @default.
• W2103187519 hasAuthorship W2103187519A5054422500 @default.
• W2103187519 hasAuthorship W2103187519A5073466449 @default.
• W2103187519 hasAuthorship W2103187519A5085188591 @default.
• W2103187519 hasConcept C109316439 @default.
• W2103187519 hasConcept C143425029 @default.
• W2103187519 hasConcept C147897179 @default.
• W2103187519 hasConcept C151730666 @default.
• W2103187519 hasConcept C153911025 @default.
• W2103187519 hasConcept C175156509 @default.
• W2103187519 hasConcept C185592680 @default.
• W2103187519 hasConcept C190283241 @default.
• W2103187519 hasConcept C202751555 @default.
• W2103187519 hasConcept C2776232574 @default.
• W2103187519 hasConcept C2776694085 @default.
• W2103187519 hasConcept C2778119113 @default.
• W2103187519 hasConcept C2778707968 @default.
• W2103187519 hasConcept C2780500152 @default.
• W2103187519 hasConcept C2781121885 @default.
• W2103187519 hasConcept C43369102 @default.
• W2103187519 hasConcept C502942594 @default.
• W2103187519 hasConcept C54355233 @default.
• W2103187519 hasConcept C552990157 @default.
• W2103187519 hasConcept C55493867 @default.
• W2103187519 hasConcept C81885089 @default.
• W2103187519 hasConcept C86803240 @default.
• W2103187519 hasConceptScore W2103187519C109316439 @default.
• W2103187519 hasConceptScore W2103187519C143425029 @default.
• W2103187519 hasConceptScore W2103187519C147897179 @default.
• W2103187519 hasConceptScore W2103187519C151730666 @default.
• W2103187519 hasConceptScore W2103187519C153911025 @default.
• W2103187519 hasConceptScore W2103187519C175156509 @default.
• W2103187519 hasConceptScore W2103187519C185592680 @default.
• W2103187519 hasConceptScore W2103187519C190283241 @default.
• W2103187519 hasConceptScore W2103187519C202751555 @default.
• W2103187519 hasConceptScore W2103187519C2776232574 @default.
• W2103187519 hasConceptScore W2103187519C2776694085 @default.
• W2103187519 hasConceptScore W2103187519C2778119113 @default.
• W2103187519 hasConceptScore W2103187519C2778707968 @default.
• W2103187519 hasConceptScore W2103187519C2780500152 @default.
• W2103187519 hasConceptScore W2103187519C2781121885 @default.
• W2103187519 hasConceptScore W2103187519C43369102 @default.
• W2103187519 hasConceptScore W2103187519C502942594 @default.
• W2103187519 hasConceptScore W2103187519C54355233 @default.
• W2103187519 hasConceptScore W2103187519C552990157 @default.
• W2103187519 hasConceptScore W2103187519C55493867 @default.
• W2103187519 hasConceptScore W2103187519C81885089 @default.
• W2103187519 hasConceptScore W2103187519C86803240 @default.
• W2103187519 hasIssue "5" @default.
• W2103187519 hasLocation W21031875191 @default.
• W2103187519 hasOpenAccess W2103187519 @default.
• W2103187519 hasPrimaryLocation W21031875191 @default.

• next